June 2026
MDMA
What June 2026's 19 new studies found, synthesized from the papers below. All MDMA research →
The synthesis
Synthesized from 19 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for MDMA, ecstasy, molly, methylenedioxymethamphetamine, then ranked by relevance.
In June 2026, research on MDMA focused on both therapeutic efficacy and recreational risks. Clinical trials and a meta-analysis reported significant reductions in PTSD and social anxiety symptoms with MDMA-assisted therapy, though methodological concerns about blinding and expectancy persist. Recreational use studies highlighted high prevalence, frequent poly-drug use, and a shift toward MDA in seized ecstasy samples, while a small naturalistic study linked weekend use to a transient Monday mood decline. Overall, the evidence supports therapeutic promise but is tempered by small samples, open-label designs, and unresolved methodological limitations.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Consumo recreativo de MDMA: un estudio sobre jóvenes en España 2026 | mixed-methods design | 1412 | Supports | MDMA was predominantly used in recreational contexts with high past-year prevalence (80.6%), but only 27.5% adhered to recommended dosing intervals and use often involved combining with alcohol and cannabis. |
| Psychometric validation of the French version of the five-dimensional altered states of consciousness questionnaire (5D-ASC) and associated 11 OAV subscales. 2026 | psychometric validation study | 777 | Supports | The French 5D-ASC questionnaire showed preliminary psychometric validity, with the 11-subscale structure demonstrating better fit than higher-order models and measurement invariance across substance categories. |
| Protocol for a qualitative mechanistic study of MDMA with a sample of psychoanalytic psychotherapists: A phenomenological investigation 2026 | qualitative mechanistic study | 25 | Unclear | This protocol describes a planned qualitative study to develop a theoretically grounded model of MDMA's psychological mechanisms of action; no results are reported. |
| MDMA-induced CYP2D6 inhibition: concentration-dependent variability using dextromethorphan as a probe 2026 | animal study | 32 | Supports | MDMA-induced CYP2D6 inhibition appeared prolonged when measured with a saturated concentration of dextromethorphan compared to a therapeutic concentration, indicating concentration-dependent variability. |
| Blinding, Expectancy, and the Active Placebo Paradox in MDMA Research. 2026 | theoretical or philosophical paper | Unclear | Argues that the active placebo paradox—where MDMA's strong subjective effects compromise blinding—challenges the validity of standard placebo-controlled trials and requires alternative methodological designs. | |
| Clinical and non-clinical use of MDMA. 2026 | theoretical/commentary | Unclear | This commentary discusses clinical and non-clinical use of MDMA; no specific findings are reported. | |
| Shifting Patterns in Ecstasy Use: Increasing Detection of MDA in Forensic Seizures and Toxicological Cases in Southern Brazil 2026 | observational study | Supports | MDA was detected more frequently than MDMA in seized drug samples and biological specimens, indicating a shift in ecstasy use patterns in Brazil. | |
| Semi-Quantitative Estimation of MDMA Tablet Dosage and Cocaine/Ketamine Purity Using a Simple to Operate Field-Portable Device 2026 | observational study with machine learning model development and validation | 62 | Supports | Deep learning models paired with Hybridized Spectral Fingerprinting achieved 98% accuracy for MDMA dosage classification and 96% accuracy for cocaine/ketamine purity estimation on external test sets. |
| Psychedelic-Assisted Psychotherapy for the Treatment of PTSD: A Systematic Review and Meta-Analysis 2026 | systematic review and meta-analysis | 358 | Supports | MDMA-assisted psychotherapy demonstrated a significant moderate-to-large reduction in PTSD symptom severity with negligible heterogeneity, while ketamine and cannabidiol did not show significant or clear benefit. |
| Understanding How Trait Negative Emotionality (NEM) Influences Social Connectedness and Responses to ± 3,4-Methylenedioxymethamphetamine (MDMA) 2026 | secondary analysis of a within-subject, double-blind, placebo-controlled trial | 30 | Mixed | Negative Emotionality did not predict baseline friendliness or changes in social connectedness, but showed a trend-level association with greater MDMA-induced peak friendliness change and predicted MDMA-induced oxytocin release after accounting for sex. |
| The Role of the Basolateral and Central Amygdala During Heroin Withdrawal and 3,4-Methylenedioxymethamphetamine Administration 2026 | experimental study | Supports | MDMA administration during heroin withdrawal may cause heightened astrocytic reactivity in the basolateral amygdala, as indicated by a significant interaction between MDMA and heroin on GFAP immunoreactivity. | |
| Happy water overdose: A trending but fatal street drug 2026 | case study | 2 | Opposes | Two patients who consumed 'Happy water' tested positive for MDMA, methamphetamine, diazepam, and tramadol, and the cocktail's unpredictable composition poses acute risks of overdose and death. |
| MDMA-Assisted Therapy for Social Anxiety Disorder: A Randomized, Open-label, Wait-list Controlled Trial 2026 | randomized controlled trial | 20 | Supports | MDMA-Assisted Therapy led to a significantly greater reduction in social anxiety symptoms than a waitlist condition, with a mean difference of −43.3 on the Liebowitz Social Anxiety Scale. |
| Comparison of acute effects of 3,4-methylenedioxymethamphetamine (MDMA) with and without a supplemental booster dose in healthy participants: a double-blind, randomized, placebo-controlled, crossover study 2026 | double-blind, randomized, placebo-controlled, cross-over study | 23 | Supports | A 60 mg booster dose of MDMA given 2 hours after an initial 120 mg dose prolonged the duration of acute subjective drug effects compared with a single dose alone (5.6 ± 1.8 h vs. 4.6 ± 1.2 h, p = 0.001). |
| Monday mood decline after weekend ecstasy use: A retrospective analysis of daily diary reports. 2026 | naturalistic study | 17 | Mixed | Monday mood was lower after ecstasy-use weekends, but this effect was attenuated when hours in bed were accounted for, suggesting recovery-related behavior largely explained the decline. |
| From therapeutic promise to evidentiary discipline: Reassessing MDMA-assisted psychotherapy for posttraumatic stress disorder. 2026 | commentary | Unclear | Argues that unresolved scientific challenges—including blinding difficulties, expectancy effects, and lack of active comparators—are central to interpreting MDMA-assisted psychotherapy for PTSD, and that broader recovery indicators beyond symptom reduction are needed. | |
| VA launches MDMA‐assisted mental health therapy trial 2026 | clinical trial | Unclear | The VA has launched a clinical trial to evaluate the safety and efficacy of MDMA-assisted therapy for treating severe mental health disorders, including PTSD and alcohol use disorder. | |
| Synthetic Drugs and Behavioural Addictions: LSD, MDMA and Digital Toxicity 2026 | theoretical or philosophical paper | Unclear | Argues that Ayurvedic concepts can provide a systems-biology paradigm for understanding synthetic drug abuse and behavioral addictions, linking them to modern neurobiological mechanisms. | |
| Exploring Attitudes Toward MDMA-Assisted Therapy in Mental Health Care 2026 | cross-sectional survey | 40 | Mixed | Healthcare professionals show cautious optimism toward MDMA-assisted therapy, with most supporting further research but identifying legal, standardization, and training barriers. |
MDMA was predominantly used in recreational contexts with high past-year prevalence (80.6%), but only 27.5% adhered to recommended dosing intervals and use often involved combining with alcohol and cannabis.
mixed-methods design Sample size: 1412
The French 5D-ASC questionnaire showed preliminary psychometric validity, with the 11-subscale structure demonstrating better fit than higher-order models and measurement invariance across substance categories.
psychometric validation study Sample size: 777
This protocol describes a planned qualitative study to develop a theoretically grounded model of MDMA's psychological mechanisms of action; no results are reported.
qualitative mechanistic study Sample size: 25
MDMA-induced CYP2D6 inhibition appeared prolonged when measured with a saturated concentration of dextromethorphan compared to a therapeutic concentration, indicating concentration-dependent variability.
animal study Sample size: 32
Argues that the active placebo paradox—where MDMA's strong subjective effects compromise blinding—challenges the validity of standard placebo-controlled trials and requires alternative methodological designs.
theoretical or philosophical paper
This commentary discusses clinical and non-clinical use of MDMA; no specific findings are reported.
theoretical/commentary
MDA was detected more frequently than MDMA in seized drug samples and biological specimens, indicating a shift in ecstasy use patterns in Brazil.
observational study
Deep learning models paired with Hybridized Spectral Fingerprinting achieved 98% accuracy for MDMA dosage classification and 96% accuracy for cocaine/ketamine purity estimation on external test sets.
observational study with machine learning model development and validation Sample size: 62
MDMA-assisted psychotherapy demonstrated a significant moderate-to-large reduction in PTSD symptom severity with negligible heterogeneity, while ketamine and cannabidiol did not show significant or clear benefit.
systematic review and meta-analysis Sample size: 358
Negative Emotionality did not predict baseline friendliness or changes in social connectedness, but showed a trend-level association with greater MDMA-induced peak friendliness change and predicted MDMA-induced oxytocin release after accounting for sex.
secondary analysis of a within-subject, double-blind, placebo-controlled trial Sample size: 30
MDMA administration during heroin withdrawal may cause heightened astrocytic reactivity in the basolateral amygdala, as indicated by a significant interaction between MDMA and heroin on GFAP immunoreactivity.
experimental study
Two patients who consumed 'Happy water' tested positive for MDMA, methamphetamine, diazepam, and tramadol, and the cocktail's unpredictable composition poses acute risks of overdose and death.
case study Sample size: 2
MDMA-Assisted Therapy led to a significantly greater reduction in social anxiety symptoms than a waitlist condition, with a mean difference of −43.3 on the Liebowitz Social Anxiety Scale.
randomized controlled trial Sample size: 20
A 60 mg booster dose of MDMA given 2 hours after an initial 120 mg dose prolonged the duration of acute subjective drug effects compared with a single dose alone (5.6 ± 1.8 h vs. 4.6 ± 1.2 h, p = 0.001).
double-blind, randomized, placebo-controlled, cross-over study Sample size: 23
Monday mood was lower after ecstasy-use weekends, but this effect was attenuated when hours in bed were accounted for, suggesting recovery-related behavior largely explained the decline.
naturalistic study Sample size: 17
Argues that unresolved scientific challenges—including blinding difficulties, expectancy effects, and lack of active comparators—are central to interpreting MDMA-assisted psychotherapy for PTSD, and that broader recovery indicators beyond symptom reduction are needed.
commentary
The VA has launched a clinical trial to evaluate the safety and efficacy of MDMA-assisted therapy for treating severe mental health disorders, including PTSD and alcohol use disorder.
clinical trial
Argues that Ayurvedic concepts can provide a systems-biology paradigm for understanding synthetic drug abuse and behavioral addictions, linking them to modern neurobiological mechanisms.
theoretical or philosophical paper
Healthcare professionals show cautious optimism toward MDMA-assisted therapy, with most supporting further research but identifying legal, standardization, and training barriers.
cross-sectional survey Sample size: 40
Points of agreement
- MDMA-assisted therapy shows significant symptom reduction for PTSD and social anxiety disorder in clinical trials and meta-analyses.
- Recreational MDMA use is associated with high prevalence, frequent poly-drug use, and potential harms such as overdose and mood decline.
- Methodological challenges, particularly blinding and expectancy effects, are widely acknowledged as limitations in MDMA research.
- There is a need for better measurement tools and monitoring of MDMA use patterns, including shifts toward MDA.
Conflicts
- The meta-analysis found MDMA-assisted therapy effective for PTSD, while a commentary argues that unresolved methodological issues undermine the evidence base.
- The naturalistic study found Monday mood decline after ecstasy use, but this was largely explained by sleep/inactivity, conflicting with the idea of direct residual drug effects.
- The animal study showed prolonged CYP2D6 inhibition with saturated probe concentrations but not with therapeutic concentrations, indicating conflicting results depending on methodology.
Gaps
- Durability of treatment gains beyond short-term follow-up is not established.
- Blinding and expectancy effects remain unresolved; active comparator trials are lacking.
- Most clinical trials have small sample sizes and lack diversity in populations.
- Long-term safety and neurobiological mechanisms of MDMA, especially with booster doses, are not fully understood.
- Recreational use studies rely on self-report and naturalistic designs; objective monitoring is limited.
- The shift toward MDA in seized drugs requires more toxicological and clinical characterization.